Literature DB >> 15933573

Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility.

Entesar Husain1, Sue Whitehead, Annette Castell, Eva E Thomas, David P Speert.   

Abstract

Our aim was to determine the significance of species identification and penicillin susceptibility of viridans streptococci in children with malignancies. Streptococcus mitis accounted for 58% of invasive viridans streptococcal infections of which 51% were penicillin-nonsusceptible. There was no significant association between species or penicillin susceptibility pattern and clinical presentation or outcome.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15933573     DOI： 10.1097/01.inf.0000164708.21464.03

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  18 in total

1.  Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience.

Authors:  J Radocha; P Paterová; A Zavřelová; B Víšek; F Gabalec; H Žemličková; P Žák
Journal:  Folia Microbiol (Praha)       Date:  2017-08-03       Impact factor: 2.099

2.  Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Authors:  C Garcia-de-la-Maria; Y Q Xiong; J M Pericas; Y Armero; A Moreno; N N Mishra; M J Rybak; T T Tran; C A Arias; P M Sullam; A S Bayer; J M Miro
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  GyrB polymorphisms accurately assign invasive viridans group streptococcal species.

Authors:  Jessica Galloway-Peña; Pranoti Sahasrabhojane; Jeffrey Tarrand; Xiang Y Han; Samuel A Shelburne
Journal:  J Clin Microbiol       Date:  2014-06-04       Impact factor: 5.948

4.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

Review 5.  It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations.

Authors:  Christopher D Doern; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

6.  Saliva improves Streptococcus mitis protective effect on human gingival fibroblasts in presence of 2-hydroxyethyl-methacrylate.

Authors:  Mara Di Giulio; Viviana di Giacomo; Emanuela Di Campli; Soraya Di Bartolomeo; Susi Zara; Guido Pasquantonio; Amelia Cataldi; Luigina Cellini
Journal:  J Mater Sci Mater Med       Date:  2013-05-14       Impact factor: 3.896

7.  Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia.

Authors:  S B Han; E Y Bae; J W Lee; D G Lee; N G Chung; D C Jeong; B Cho; J H Kang; H K Kim
Journal:  Infection       Date:  2013-05-03       Impact factor: 3.553

8.  Streptococcus mitis strains causing severe clinical disease in cancer patients.

Authors:  Samuel A Shelburne; Pranoti Sahasrabhojane; Miguel Saldana; Hui Yao; Xiaoping Su; Nicola Horstmann; Erika Thompson; Anthony R Flores
Journal:  Emerg Infect Dis       Date:  2014-05       Impact factor: 6.883

9.  The Role of Corticosteroids in Adult Respiratory Distress Syndrome caused by Viridans Group Streptococci Bacteremia in Neutropenic Patients.

Authors:  Abraham T Yacoub; Lysenia Mojica; Lily Jones; Andrea Knab; Sally Alrabaa; John Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-01       Impact factor: 2.576

10.  Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children.

Authors:  Seung Beom Han; E Young Bae; Jae Wook Lee; Dong-Gun Lee; Nack-Gyun Chung; Dae-Chul Jeong; Bin Cho; Jin Han Kang; Hack-Ki Kim
Journal:  BMC Infect Dis       Date:  2013-06-17       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.